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Objective. To compare long-term quality of life outcomes after treating early stage oropharyngeal carcinoma either with surgery,
surgery combined with radiotherapy, or surgery combined with chemoradiotherapy. Methods. Questionnaire based method: 111
eligible patients agreed to fill out a quality of life questionnaire. Results. Of the 32 scales contained in the EORTC’s combined
QLQ-C30 and HN35, 11 scales show significantly better results for the surgery-only treatment group when compared to either
surgery combined with radiotherapy or surgery combined with any type of adjuvant therapy. These eleven scales are role function
(𝑃 = 0.019/0.008), social function (𝑃 = 0.01/0.034), nausea (𝑃 = 0.017/0.025), pain (𝑃 = 0.014/0.023), financial problems
(𝑃 = 0.030/0.012), speech (𝑃 = 0.02/0.015), social eating (𝑃 = 0.003/<0.001), mouth opening (𝑃 = 0.033/0.016), sticky saliva
(𝑃 = 0.001/<0.001), swallowing (𝑃 < 0.001/<0.001), and dry mouth (𝑃 < 0.001/0.001). Conclusion. Treatment of early stage
oropharyngeal carcinoma with surgery alone has definite advantages over treatments including any form of adjuvant therapy when
considering quality of life. Advantages manifest themselves especially in functional aspects of the head and neck realm; however
general health aspects as well as psychosocial aspects show improvements as well. This study does not show any indication of
QOL-related drawbacks of surgery-only treatment approaches.
1. Introduction
Oropharyngeal Carcinomas (OPCs) represent up to 3% of
all new cancer diagnoses in the United States and are a
commonly occurring cancer of the head and neck region
[1, 2]. Usually, these OPCs are diagnosed in more advanced
stages and have poor prognosis. However, when they are
diagnosed early on (at stages T1 and T2), they have good five-
year survival estimates [3, 4]. Upon diagnosis in their early
stages, transoral tumor resection alone or in combination
with adjuvant radiotherapy or chemoradiotherapy offers
very good oncologic results [5, 6]. All of these treatment
modalities have showed their effectiveness in increasing
survival estimates [7–9]. Since oncologic results are excellent,
impact on quality of life becomes important when choosing
treatment modality for the individual patient [10].
The uniqueness of the oropharyngeal anatomical region
stems from its functional importance in activities such as
eating and speaking. In addition, its highly exposed nature
allows potential aesthetic defects to have a strong stigmatizing
effect. Given these key functional and social aspects, and
the fact that OPC as well as the different treatment options
can have severe effects on all of these factors, it should be
of no surprise that the patients’ subjective quality of life
(QOL) could be severely affected on social, physical, and
psychological levels.
Considering the potentially different effect onQOL stem-
ming from methodically different but comparably effective
treatment methods, expected QOL outcomes should be an
important factor when choosing the appropriate therapeutic
approach [11]. Publicly, nonsurgical treatment methods are
perceived as less invasive and thus are often favored due to the
assumption that there may be a better QOL outcome [12, 13].
There is little conclusive data to support this conclusion and
this study aims to shed light with regard to this issue. Further-
more, the aim of this study is to compare the QOL in patients
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after transoral resection of a small OPC with or without
adjuvant treatment, in order to better understand the impact
of the various parts of a multimodal treatment (surgery,
radiotherapy, and chemotherapy) in long-term QOL.
2. Methods
The Ethics Commission of the FAU Erlangen-Nürnberg
reviewed and subsequently approved the intended patient
selection process and the study protocol as well as the
required patient consent form. In order to be considered
for the study, patients had to meet the following inclusion
criteria: (1) tumor was located within the oropharynx, (2)
primary tumor was of early stage (pT1 or pT2, N0-2), (3)
no distant metastasis were detected (M0), (4) tumor was
successfully treated with a minimum tumor free interval of
18 months after treatment, and (5) tumor was not a relapse of
a previously existing tumor. The different forms of treatment
considered were surgery alone (OP) or a combination of
surgery and radio- and/or chemotherapy (OPRT/OPRCT).
Excluded were all patients with a recurrent disease. For the
purpose of this study, OPCs are defined as all carcinomas
falling under the following groups of the ICD-10: C01, C05
without C05.0, C09, and C10.
An existing database comprised of follow-up patients
with treated primary oropharyngeal carcinoma combined
with a thorough screening of patients coming in for routine
posttreatment follow-up was used to identify 160 eligible
candidates.
Patients’ QOL was evaluated in detail using German-
language versions of two standardized questionnaires from
the European Organization for Research and Treatment
of Cancer (EORTC), specifically the Core Module [14]
(EORTC-QLQ-C30) and the Head and Neck Cancer Module
[15] (EORTC-QLQ-H&N35). The Core Module is designed
as an assessment tool for cancer patients. It evaluates a total
of nine multi-item scales including five functional scales
(physical, role, cognitive, emotional, and social) and three
symptom scales (fatigue, pain, and nausea and vomiting)
as well as a global health and QOL-scale. Additionally, a
number of single-item symptommeasures are included. This
Core Module is supplemented by the Head and Neck Can-
cer Module consisting of six multi-item scales designed to
capture issues associated with cancers of the specified region
and their treatment (pain, swallowing, speech, social eating,
social contacts, and sexuality). In both modules, achievable
scores for each scale range from zero to one hundred. Higher
scores represent higher response levels; that is, in functional
scales, a high score implicates more positive outcomes while
high scores in symptom scales are congruent with more neg-
ative outcomes. Statistical analysis of the acquired data was
done according to EORTC-QLQ scoring instructions. The
resulting, dichotomized and grouped scores were compared
and checked for significance using chi-square independence
tests or Fischer tests when necessary for OP versus OPRT as
well as for OP versus patients who received surgery and any
form of adjuvant therapy (OP + adj).The latter group consists
of OPRT as well as OPRCT.The phi-coefficient was used as a
measure of association for significant results.
Missing items within the EORTC-QLQ were a minor
issue when reviewing the questionnaires. Seven question-
naires that were sent out for home answering were missing
items 9–19 of EORTC-QLQ-H&N35due to a systematic error.
Since the omissions were caused by a systematic error and
not by patients’ refusal to answer certain questions (because
they felt uncomfortable to do so for instance) considering
these single items as lost should have no further impact on
the statistical proceedings. These single missing items were
considered lost and not processed further.
The use of adjuvant therapy in form of RT or RCT was
decided in our tumor board. Irradiation typically included
the primary tumor site and the involved side of the neck.
Various changes in treatment protocols, as well as techni-
cal developments, have been noted over the years. Today,
however, typical indications for RCT include the presence of
positive surgical margins when further surgery was not feasi-
ble, advanced neck disease, and extracapsular tumor spread.
Typical indications for adjuvant RT include close margins,
solitary cervical metastasis, and infiltration of lymph vessels
or nerves in permanent histology. Sometimes a combination
of soft criteria such as poor differentiation, large tumor
dimension, or large tumor depth can result in offering the
patient an adjuvant RT.
The standard tumor follow-up protocol of the ENT
department was used to examine patients’ medical status.
This consisted of a patient interview and inspecting the
treated regions visually (with aid of scopes), by palpation and,
in indicated circumstances, by ultrasound. Results that were
relevant to this study were documented on a form separate
from the patient questionnaire.
3. Results
Of all eligible candidates, 111 volunteered to participate in
the study anonymously between June 2011 and June 2012.
85 participants were males and 26 females. 80 patients were
seen in person while 31 individuals preferred to participate
by answering the questionnaire via mail. 26 patients were
treated with surgery as their only form of treatment (OP-
Group) while 33 patients received additional radiotherapy
(OPRT-Group) and 52 patients had additional radiotherapy
as well as chemotherapy (OPRCT-Group). Treated tumor
sizes in all three groups were comparable. Detailed patient
demographics according to therapy group are presented in
Table 1.
The results of the EORTC-QLQ-C30 and the EORTC-
QLQ/H&N35 for treatment groups OP, OPRT, and OPRCT
are shown in Tables 2 and 3, respectively.
Table 4 contains four questionnaire scales (2 from
EORTC-QLQ-C30 and 2 from EORTC-QLQ-HN35). For
each item comparisons are made with regard to the percent-
age of patients that report a full score versus the percentage
of patients that report a less than maximum score. A score
of “100” can be equated with an optimal outcome. Items
“role function” as well as “social function” (marked with
italic font) show that the percentage of patients without any
loss of function in these aspects is significantly higher when
compared to OPRT or OP + adj treatment groups.
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Table 1: Detailed description of demographics, treatment modalities, and histological differentiation according to therapy.
Characteristics OP OPRT OPRCT


























Base of the tongue: 5 (19.2%)
Palatine tonsil: 9 (34.6%)
Palatal arch 11 (42.3%)
Oropharynx NOS: 1 (3.8%)
Base of the tongue: 8 (23.5%)
Palatine tonsil: 18 (52.9%)
Palatal arch 5 (14.7%)
Oropharynx NOS: 3 (8.8%)
Base of the tongue: 13 (25.5%)
Palatine tonsil: 31 (60.8%)
Palatal arch 2 (3.9%)
Oropharynx NOS: 5 (9.8%)

























Neck dissection Yes: 20 (76.9%)No: 6 (23.1%) Yes: 34 (100%) Yes: 51 (100%)













∗Tumor-depth is a calculated function of tumor extent and depth of infiltration.
TLM: transoral laser microsurgery, RT: radiotherapy, and RCT: radiochemotherapy.
Table 5 is comprised of twenty-two scales (EORTC-QLQ-
C30: 9, EORTC-QLQ-HN35: 13). These scales are compared
as to how many patients reported scores of zero versus how
many patients reported scores above zero. For all items, a
response of “0” represented a better outcome for the patient.
Seven of these scales (EORTC-QLQ-C30: 3, EORTC-QLQ-
HN35: 4) show significant correlation with 𝑃 ≤ 0.05. For all
seven scales (nausea, pain, financial problems, HN speech,
HN social eating, HN opening mouth, and HN sticky saliva),
a surgery-only approach yielded more patients who reported
optimal results when compared to OPRT and OP + adj. Five
items of the scale HN social eating are missing answers due
to the aforementioned systematic error, however, only to a
negligible extent such that there is no effect on the trend.
The six final items (EORTC-QLQ-C30: 3, EORTC-QLQ-
HN35: 3) as well as the overall Quality of Life score are
compared in Table 6. The table reflects how many patients of
each treatment group reported above- versus below-average
outcomes. Notably, higher scores in the EORTC-QLQ-C30
items represent better outcomes, whereas lower scores in
EORTC-QLQ-HN35 items are better. Items “HN swallowing”
and “HN dry mouth” have significant results (𝑃 ≤ 0.05)
illustrating that an above-average number of members of the
surgery-only treatment group reported below-average scores,
that is, above-average outcomes.
4. Discussion
Quality of life (QOL) is a complex, multifaceted construct
that is challenging to accurately measure. With the advent
of tools, such as the EORTC’s set of QOL-questionnaires
some two decades ago, the possibility of comparingmedically
influenced outcomes on QOL allowed researchers to look
beyond survival as the sole measure of successful medical
intervention. This becomes especially valuable when faced
with medical interventions that generate similar survival
estimates and may primarily differ in terms of patients’
perceived QOL. Currently, there are few studies comparing
QOL outcomes in different treatment modalities of OPC [11,
13]. Many of these focus on the aftermath of advanced OPC
while little research about early stage OPCs has surfaced [12].
Tschiesner et al. andMowry et al. both come to the conclusion
that treatments involving surgery have more desirable QOL-
outcomes for advanced stage OPCs [4, 16]. In this particular
4 BioMed Research International









Global health status 75.00 (62.79–80.16) 66.67 (56.85–72.95) 66.67 (59.22–70.91)
Functional scales
Physical 100 (87.33–97.28) 86.67 (75.34–88.30) 93.33 (79.68–91.66)
Role 100 (85.28–98.05) 83.33 (58.70–82.71) 83.33 (64.70–81.46)
Emotional 83.33 (72.59–88.95) 75.00 (59.79–80.79) 83.33 (66.66–80.99)
Cognitive 100 (80.90–96.02) 83.33 (68.77–87.80) 100 (76.23–89.79)
Social 100 (78.80–98.13) 83.33 (64.59–85.92) 100 (71.26–86.43)
Symptom scales
Fatigue 16.67 (13.25–31.20) 22.22 (20.16–41.45) 27.78 (22.09–39.02)
Nausea and vomiting 0 (−0.68–1.96) 0 (2.39–11.75) 0 (1.78–9.76)
Pain 0 (5.16–21.77) 16.67 (18.31–39.26) 16.67 (17.18–34.75)
Dyspnea 0 (9.79–33.80) 0 (8.53–29.86) 0 (11.15–27.31)
Insomnia 0 (14.64–41.77) 0 (11.24–35.23) 0 (16.52–37.33)
Appetite loss 0 (−1.08–16.47) 0 (8.12–30.26) 0 (8.68–27.22)
Constipation 0 (2.26–20.82) 0 (5.68–28.66) 0 (3.16–16.07)
Diarrhea 0 (1.94–18.57) 0 (2.15–14.01) 0 (1.37–10.16)
Financial problems 0 (−2.17–20.11) 0 (7.74–24.58) 0 (12.26–28.76)









HN pain 0 (3.37–13.97) 8.33 (8.37–24.39) 8.33 (12.40–24.76)
HN swallowing 0 (3.78–20.88) 25.00 (19.34–32.39) 20.83 (18.82–29.44)
HN senses 0 (2.72–15.94) 0 (8.15–29.78) 0 (11.69–27.20)
HN speech 0 (0.58–16.31) 11.11 (11.67–28.18) 0 (9.39–22.56)
HN social eating 0 (2.25–22.42) 25.00 (16.18–37.65) 20.833 (18.97–35.20)
HN social contact 0 (0.48–6.45) 0 (3.21–19.32) 0 (4.21–13.29)
HN sexuality 0 (8.08–31.92) 0 (12.14–39.58) 0 (17.08–37.78)
HN teeth 0 (6.54–36.13) 0 (16.11–48.25) 0 (17.59–40.74)
HN opening mouth 0 (5.68–34.32) 33.33 (22.67–50.89) 33.33 (25.58–46.64)
HN dry mouth 0 (14.30–44.36) 100 (66.78–89.54) 66.67 (49.93–72.29)
HN sticky saliva 0 (3.60–23.06) 66.67 (37.11–66.33) 66.67 (37.50–59.72)
HN coughed 0 (12.41–35.59) 33.33 (16.65–40.82) 33.33 (23.38–41.89)
HN felt ill 0 (3.03–15.64) 0 (1.71–23.58) 0 (8.20–25.14)
HN pain killers 0 (19.36–60.64) 0 (10.28–44.89) 0 (17.65–44.85)
HN nutritional supplements 0 (−4.26–12.26) 0 (7.57–40.70) 0 (5.73–27.60)
HN feeding tube 0 (−1.69–25.69) 0 (−2.91–16.71) 0 (0.22–16.44)
HN weight loss 0 (6.01–41.99) 0 (0.44–27.14) 0 (2.80–22.20)
HN weight gain 0 (9.08–46.92) 0 (0.44–27.14) 0 (−0.85–13.35)
study, long-term outcomes of different treatment modalities
for early stage OPC are considered the deciding factor when
choosing a course of treatment for patients.
As shown in previous studies, individuals with limited
OPC make up a group of patients with excellent oncologic
result [5, 17]. A transoral resection of the tumor is possible
in most cases. The development of laser microsurgery and
transoral robotic surgery improves the effectiveness of sur-
gical treatment [18]. In a recently published study we were
able to show that in the absence of certain prognostic factors
BioMed Research International 5
Table 4: Comparing OP with OPRT and OP + adj—scale group 1 (percent within therapy group).
Item OP OPRT OP + adj OP versus OPRTP/Phi
OP versus OP + adj
P/PhiScore 100 >100 100 >100 100 >100
Role function 73.1 26.9 42.4 57.6 43.5 56.5 0.019/0.268 0.008/0.250
Social function 73.1 26.9 39.4 60.6 49.4 50.6 0.01/0.336 0.034/0.201
HN sexuality 61.5 38.5 51.5 48.5 54.1 45.9 NS NS
HN nutritional supplements 96.2 3.8 76.7 23.3 80.0 20.0 0.038/0.278 NS
NS: Results are statistically not significant.
Table 5: Comparing OP with OPRT and OP + adj—scale group 2 (percent within therapy group).
Item OP OPRT OP + adj OP versus OPRTP/Phi
OP versus OP + adj
P/PhiScore 0 >0 0 >0 0 >0
Fatigue 30.8 69.2 30.3 69.7 32.9 67.1 NS NS
Nausea 96.2 3.8 72.7 27.3 76.5 23.5 0.017/0.310 0.025/0.213
Pain 65.4 34.6 33.3 66.7 40.0 60.0 0.014/0.319 0.023/0.216
Dyspnea 57.7 42.3 66.7 33.3 64.7 35.3 NS NS
Insomnia 53.8 46.2 60.0 40.0 60.0 40.0 NS NS
Appetite loss 84.6 15.4 69.7 30.3 71.8 28.2 NS NS
Constipation 76.9 23.1 72.7 27.3 78.8 21.2 NS NS
Diarrhea 76.9 23.1 78.8 21.2 83.5 16.5 NS NS
Financial problems 88.5 11.5 63.6 36.4 62.4 37.6 0.030/0.283 0.012/0.238
HN pain 53.8 46.2 42.4 57.6 40.0 60.0 NS NS
HN speech 73.1 26.9 33.3 66.7 45.9 54.1 0.002/0.395 0.015/0.231
HN social eating 65.4 34.6 27.3 72.7 25.9 74.1 0.003/0.381 <0.001/0.350
HN social contact 76.9 23.1 51.5 48.2 60.0 40.0 0.045/0.261 NS
HN teeth∗ 68.0 32.0 53.3 46.7 57.0 43.0 NS NS
HN opening mouth∗ 72.0 28.0 43.3 56.7 44.3 55.7 0.033/0.288 0.016/0.237
HN sticky saliva∗ 72.0 28.0 26.7 73.3 29.1 70.9 0.001/0.470 <0.001/0.375
HN coughed∗ 52.0 48.0 50.0 50.0 41.8 58.2 NS NS
HN felt ill∗ 72.0 28.0 80.0 20.0 73.4 26.6 NS NS
HN pain killers 61.5 38.5 66.7 33.3 54.1 45.9 NS NS
HN feeding tube 88.5 11.5 90.0 10.0 91.8 8.2 NS NS
HN weight loss 76.9 23.1 83.3 16.7 85.9 14.1 NS NS
HN weight gain 73.1 26.9 83.3 16.7 89.4 10.6 NS 0.045/−0.200
∗Items were calculated with a total of 7 missings. This is due to a systematic error described more closely in Materials and Methods section.
NS: results are statistically not significant.
Table 6: Comparing OP with OPRT and OP + adj—scale group 3 (percent within therapy group).
Item Median score OP OPRT OP + adj OP versus OPRTP/Phi
OP versus OP + adj
P/Phi<Median ≥Median <Median ≥Median <Median ≥Median
Overall QOL 66.667 19.2 80.8 27.3 72.7 35.3 64.7 NS NS
Physical function 93.33 26.9 73.1 63.6 36.4 48.2 51.8 0.005/−0.307 NS
Emotional function 83.33 30.8 69.2 51.5 48.5 48.2 51.8 NS NS
Cognitive function 83.33 15.4 84.6 30.3 69.7 27.1 72.9 NS NS
HN swallowing 16.667 69.2 30.8 21.2 78.8 25.3 74.7 <0.001/0.482 <0.001/0.398
HN senses 12.5 72.0 28 53.6 46.4 54.4 45.6 NS NS
HN dry mouth 66.67 72.0 28 16.7 83.3 29.1 70.9 <0.001/0.559 <0.001/0.375
NS: results are statistically not significant.









































































































































































Figure 1: Statistically significant results.
such as tumor dimension of less than 2 cm and tumor depth
of less than 5mm surgery as a single modality treatment
offers very good results in patients with pT1-2N0-1 OPC [3].
Another important aspect is the role of HPV infection in
OPC. Since these patients are usually younger and have a
better prognosis, desintensification of treatment is currently
being discussed for this patient group [19, 20]. Therefore
data on QOL of these patients compared to patients treated
with surgery and adjuvant radio(chemo)therapy could play
an important role in choosing the optimal treatmentmodality
[11]. We hypothesized that the expected improvements in
reported QOL when choosing surgery as the sole treatment
option were due to not exposing patients to the side effects
that may have been a consequence of additional treatments
with radio- and/or chemotherapy. Furthermore this thera-
peutic tool could be preserved for cases of recurrence of
second primary tumors, which are known to occur in up to
25% of patients. In particular, this study was aimed to look
at surgery-only treatment versus two distinct groups: surgery
combined with radiotherapy alone and surgery plus adjuvant
therapies in general. For the purpose of this study, adjuvant
therapies were either radiotherapy alone or in combination
with chemotherapy.
Regardless of treatment modality, most patients report
acceptable QOL outcomes. As is expected, the vast majority
of complaints that do exist from long-term survivors of head
and neck cancers focus on that specific region. Funk et al.
identified that the functional aspects of eating and swallowing
were most impacted by the disease [21]. The trend of these
findings is supported by this study as well [22]. Patients
treated with adjuvant therapies in particular show a similar
complaint profile that highlights loss of oral functions. It is
notable however that a large majority of OP-only patients
do not express any complaints regarding the head and neck
region in this particular sample set.
Using the general and H&N specific QOL-questionnaires
of the EORTC to facilitate comparison between outcomes
showed us statistically significant differential outcomes
within nine of the measured scales, as illustrated in Figure 1.
Six of these scales (HN speech, HN social eating, HNopening
mouth, HN sticky saliva, HN swallowing, and HN dry
mouth) are specific to the head and neck region while three
(pain, nausea, and financial problems) are identified with the
general section of the QOL-questionnaire. Scores in all nine
mentioned scales favor surgery-only treatment as having the
better outcome.The results for the physical function scale are
less conclusive, but there is a clear trend towards significance.
Apart from a small cohort size, the main limitation of
this study is the existence of numerous confounding factors,
which cannot be eliminated. Treatment modality is only
one variable that is responsible for patients’ perceived QOL.
Other factors that have been identified to impact QOL of
OPC survivors are age, gender, marital status, comorbidities,
malnutrition, and staging of the tumor [23]. These problems
should be addressed with a prospective follow-up study with
a larger cohort size.
5. Conclusion
Regardless of the treatment modality chosen for early stage
OPC, overall quality of life as determined by “Global Health
Status” of theQLQ-C30 can be considered good.Nonetheless,
it becomes apparent that treatment via surgery alone has def-
inite advantages over treatments including any form of adju-
vant therapy. Even though these advantages manifest them-
selves especially in functional aspects of the head and neck
realm, they are not exclusive to this region. General health
aspects as well as psychosocial functions seem to be improved
as well. In this study, there are no hints of a potential QOL-
related drawback of surgery-only treatment approaches.
A continuation of this study to achieve larger sample
sizes over the coming year is advisable in order to corrobo-
rate above findings and potentially discover further statisti-
cally significant differences between the treatment methods
named.
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